FDA places ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) on speedier review-path

Boston, MA 04/12/2013 (wallstreetpr) – A biotechnology company ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) (Current: $12.83, Down by 2.14%), which has annual sales of $5 million ascended by 43 percent after it said that its lead drug will gain U.S regulatory review prior to its anticipated time. Through yesterday, its shares rose five-fold in 12 months. By the end of 2014, the San Diego-based company plans on applying for a review by the Food and Drug Administration of its drug pimavanserin. Later this month, a final-phase trial was to be conducted. The company said that the FDA has agreed that Acadia will not have to conduct that particular trial.

Speedier trial
Pimavanserin is to be used for the treatment of Parkinson’s disease psychosis. Instead of the scheduled review, Acadia can now use supportive data and trial results from the various other studies that have been conducted and then seek a review of the drug. In a statement, the Chief Executive Officer of the company, Uli Hacksell said that the company is very pleased with the way the talks with the Food Drug Administration authorities progressed and the outcome has been very conducive to the company as well. This will go a long way in reducing the time and the costs associated with the PDP development program.

Progressive deterioration
Parkinson’s disease or PD is a chronic in nature. The disorder has progressive movement. This means that the symptoms not only continue but tend to worsen over a period of time. Over one million people in the U.S suffer from the disease that has no solid cure as of now and its symptoms are largely managed with medication. Acadia’s once-a-day pill primavanserin is under trial. The study that is being conducted is for the treatment of loss of contact with the real world and more often than not is accompanied by hallucinations.

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. While reading this article one must assume that we may be compensated for posting this content on our website.

Published by Nicholas Maithya

Nicholas is a Financial Analyst by profession, who enjoys writing about investments, technological developments, business, economics and other financial topics at various financial publications. Join him here on Wallstreetpr.com as he endeavors to deliver to you the latest breaking news on the above mentioned fronts. Contact him by email at nmaithya@gmail.com or follow Nicholas Kitonyi @nmaithyak on Twitter.

Recent Stories

SignUp Now For Our Featured Newsletter